Back

Impact of age on comparative outcomes of abbreviated versus standard antiplatelet therapy in patients at high bleeding risk: a pre-specified analysis from the MASTER-DAPT trial

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Targeting platelets post-percutaneous coronary intervention Antiplatelet Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Antonio Landi

Cardiocentro Ticino Institute, Lugano (Switzerland)

6 More presentations in this session

Presentation thumbnail
Short-term DAPT followed by P2Y12 monotherapy versus standard-term DAPT after PCI for ACS: an updated systematic review and meta-analysis of randomised controlled trials
Associate Professor M. Monaghan (Enniskillen, GB)
Abstract Slides
Presentation thumbnail
Ticagrelor-based dual antiplatelet therapy versus aspirin monotherapy after CABG: a systematic review and meta-analysis of randomized controlled trials
Mr R. Goes (Asa Sul Brasilia, BR)
Abstract Slides
Presentation thumbnail
Differential prognostic value of platelet reactivity and CYP2C19 phenotype in high bleeding risk patients undergoing PCI: insights from the PTRG-DES Registry
Doctor J. Cha (Seoul, KR)
Abstract Slides
Presentation thumbnail
Clopidogrel versus aspirin for secondary prevention of coronary artery disease stratified by age: an individual patient data meta-analysis of 28,982 patients from 7 randomized trials
Doctor D. Giacoppo (Catania, IT)
Abstract Slides
Presentation thumbnail
Potent P2Y12 inhibitor monotherapy without aspirin early after percutaneous coronary intervention: the NEO-MINDSET Platelet Function Substudy
Doctor P. Guimaraes (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Targeting platelets post-percutaneous coronary intervention

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparative efficacy and safety of de-escalation, abbreviation, and standard potent P2Y12 inhibitor based DAPT strategies after acute coronary syndrome: a network meta analysis
21 March 2026
thumbnail
Congress Presentation
Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients: a subgroup analysis of age
27 August 2021
thumbnail
Congress Presentation
Percutaneous coronary intervention in the age of frailty
2 September 2019
thumbnail
Congress Presentation
The comparison of short-term dual antiplatelet therapy versus standard dual antiplatelet therapy in elderly patients with coronary artery disease who underwent percutaneous coronary intervention
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources